Requirement of Cyclin E-Cdk2 Inhibition in p16 INK4a -Mediated Growth Suppression
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations of p16(INK4a) have been identified in a large number of human tumors. An established biochemical function of p16 is its ability to specifically inhibit cyclin D-dependent kinases in vitro, and this inhibition is believed to be the cause of the p16-mediated G1 cell cycle arrest after reintroduction of p16 into p16-deficient tumor cells. However, a mutant of Cdk4, Cdk4(N158), designed to specifically inhibit cyclin D-dependent kinases through dominant negative interference, was unable to arrest the cell cycle of the same cells (S. van den Heuvel and E. Harlow, Science 262:2050-2054, 1993). In this study, we determined functional differences between p16 and Cdk4(N158). We show that p16 and Cdk4(N158) inhibit the kinase activity of cellular cyclin D1 complexes through different mechanisms. p16 dissociated cyclin D1-Cdk4 complexes with the release of bound p27(KIP1), while Cdk4(N158) formed complexes with cyclin D1 and p27. In cells induced to overexpress p16, a higher portion of cellular p27 formed complexes with cyclin E-Cdk2, and Cdk2-associated kinase activities were correspondingly inhibited. Cells engineered to express moderately elevated levels of cyclin E became resistant to p16-mediated growth suppression. These results demonstrate that inhibition of cyclin D-dependent kinase activity may not be sufficient to cause G1 arrest in actively proliferating tumor cells. Inhibition of cyclin E-dependent kinases is required in p16-mediated growth suppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 1×
“Among the many cyclin-dependent kinases of the cell cycle engine, deregulation of cyclin D1-Cdk4 kinase may play a particularly important role in tumorigenesis (37).”
BackgroundTight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 2×
“To establish inducible U2OS cell lines, pUHD15-1 (6) was first trans-”
BackgroundMethodThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 2×
“Unlike the p21-p27 family of cyclin-dependent kinase inhibitors, p16 specifically inhibits cyclin D-dependent kinases in vitro (36).”
BackgroundA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 1×
“At least one regulator of cyclin D1-Cdk4, the cyclin-dependent kinase inhibitor p16, is also a known tumor suppressor gene product (17, 28) whose function is frequently lost in melanoma and in a variety of other cancers (for a review, see reference 9).”
BackgroundDeletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., & Barrett, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13742 · Cited by 1,008
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir, I., Polyak, K., Iavarone, A., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.15.1831 · Cited by 962
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899
Cited by
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Zhang, H. S., Gavin, M., Dahiya, A., Postigo, A. A., Ma, D., Luo, R. X., Harbour, J. W., & Dean, D. C. (2000) · Cell · doi:10.1016/s0092-8674(00)80625-x · Cited by 658
Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle
Ekholm, S. V., & Reed, S. I. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00151-4 · Cited by 588
Molecular Interaction Map of the Mammalian Cell Cycle Control and DNA Repair Systems
Kohn, K. W. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.8.2703 · Cited by 560
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Sicinski, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 461
DNA methylation and breast carcinogenesis
Widschwendter, M., & Jones, P. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205606 · Cited by 457
Regulation of cyclin-Cdk activity in mammalian cells
Obaya, A. J., & Sedivy, J. M. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8410-1 · Cited by 397
Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21Cip1
Perez-Roger, I. (1999) · The EMBO Journal · doi:10.1093/emboj/18.19.5310 · Cited by 329
A Common Set of Gene Regulatory Networks Links Metabolism and Growth Inhibition
Cam, H., Balciunaite, E., Blais, A., Spektor, A., Scarpulla, R. C., Young, R., Kluger, Y., & Dynlacht, B. D. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.037 · Cited by 322
Cell Cycle Control of Embryonic Stem Cells
White, J., & Dalton, S. (2005) · Stem Cell Reviews · doi:10.1385/scr:1:2:131 · Cited by 310
E2F4 and E2F5 Play an Essential Role in Pocket Protein–Mediated G1 Control
Gaubatz, S., Lindeman, G. J., Ishida, S., Jakoi, L., Nevins, J. R., Livingston, D. M., & Rempel, R. E. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00071-x · Cited by 300
The Molecular Balancing Act of p16INK4a in Cancer and Aging
LaPak, K. M., & Burd, C. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0350 · Cited by 291
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities
He, G., Siddik, Z. H., Huang, Z., Wang, R., Koomen, J., Kobayashi, R., Khokhar, A. R., & Kuang, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208474 · Cited by 264
McConnell, B. B., Gregory, F. J., Stott, F. J., Hara, E., & Peters, G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1981 · Cited by 238
Role of p14ARF in Replicative and Induced Senescence of Human Fibroblasts
Wei, W., Hemmer, R. M., & Sedivy, J. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.6748-6757.2001 · Cited by 217
Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes
Ho, A. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00263-5 · Cited by 192
Foster, J. S., Henley, D. C., Bukovsky, A., Seth, P., & Wimalasena, J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.794-810.2001 · Cited by 191
Ji, P., Jiang, H., Rekhtman, K., Bloom, J., Ichetovkin, M., Pagano, M., & Zhu, L. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.029 · Cited by 170
“9, 163–173. protocols (Jiang et al., 1998).”
Self-citationKaye, F. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205834 · Cited by 153
“Since inhibition of cyclin E activity, but not cyclin D, can induce G1 arrest of proliferating cells, the indirect suppression of CDK2:cyclin E by p27Kip1 may be the primary growth suppressor function mediated by p16 induction (Jiang et al., 1998).”
BackgroundInfluential
Metadata
- Authors
- Jiang, H., Chou, H. S., & Zhu, L.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1998-09
- Volume
- 18
- Issue
- 9
- Pages
- 5284-5290
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2169344668
- Cited by
- 113
- References
- 13
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.